2 completed, 1 not yet recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Jose Seijas Amigo: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease Inclisiran - Ischemic Heart Disease, Acute Coronary Syndrome | Phase 4 | Not yet recruiting | Jose Seijas Amigo | 50 | 2024-06-01 | 2024-05-20 |
| SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. GLP-1 receptor agonist - Weight Loss, Diabetes Mellitus, Type 2 | Completed | Jose Seijas Amigo | 140 | 2022-02-01 | 2024-02-28 | |
| Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors PCSK9 inhibitor - Cognitive Function, Hypercholesterolemia | Completed | Jose Seijas Amigo | 180 | 2020-03-01 | 2023-01-17 |
Acute Coronary Syndrome (1) · Diabetes Mellitus, Type 2 (1) · Hypercholesterolemia (1) · Myocardial Ischemia (1) · Weight Loss (1)
ALN-PCS (1)
Spain (3)